Skip to main content
SpringerLink
Log in

A Review of the Use of Infliximab to Manage Cutaneous Dermatoses

  • Review article
  • Published:
Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology

Abstract

Background

Infliximab is a chimeric monoclonal antibody that binds specifically to human tumor necrosis factor-alpha (TNF-α), decreasing the effect of the cytokine in inflammatory diseases.

Objective

The aim of this study was to review the efficacy and safety of infliximab in the treatment of dermatological diseases.

Methods

A MEDLINE search (1966–January 2003), using the keyword “infliximab” was performed to find relevant articles pertaining to the use of infliximab in dermatology.

Results

Infliximab has been used in the following dermatological diseases: psoriasis, Behçet’s disease, graft versus host disease, hidradenitis suppurativa, panniculitis, pyoderma gangrenosum, SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome, sarcoidosis, subcorneal pustular dermatosis, Sweet’s syndrome, toxic epidermal necrolysis, and Wegener’s granulomatosis. There is a generally good safety profile for infliximab, which is similar to that when it is used to treat Crohn’s disease and rheumatoid arthritis.

Conclusion

Although not approved for use in dermatological diseases, there have been numerous reports of the efficacy of infliximab in cutaneous inflammatory diseases. The most promise lies in those diseases that have increased amounts of TNF-α in the cutaneous lesions, such as psoriasis.

Sommaire

Antécédents

L’infliximab est un anticorps monoclonal chimérique qui se lie au facteur de nécrose des tumeurs alpha (TNF-α), réduisant ainsi l’effet de la cytokine dans les maladies inflammatoires.

Objectif

Passer en revue l’efficacité et l’innocuité de l’infliximab dans le traitement des maladies de la peau.

Méthodes

Une recherche dans MEDLINE (de 1966 à janvier 2003) a été effectuée afin de trouver les articles pertinents à l’usage de l’infliximab en dermatologie, au moyen du terme clé « infliximab ».

Résultats

L’infliximab a été utilisé dans le traitement des affections suivantes: psoriasis, maladie de Behçet, maladie du greffon contre l’hôte, hidrosadénite, panniculite, pyoderma gangrenosum, syndrome de SAPHO (synovite, acné pustulose palmo-plantaire, hyperostose et ostéite), sarcoïdose, dermatose pustuleuse sous-cornée, syndrome de Sweet, nécrolyse épidermique toxique et granumatulose de Wegener. Le profil d’innocuité de 1’inflimixab est généralement bon, similaire au profil d’innocuité dans le traitement de la maladie de Crohn et de la polyarthrite rhumatoïde.

Conclusion

Bien que l’infliximab ne soit pas approuvé pour le traitement des maladies de la peau, plusieurs rapports en prouvent 1’efficacité contre les maladies inflammatoires cutanées. Le traitement à l’infliximab semble le plus prometteur dans les maladies avec une forte présence de TNF-α dans les lésions cutanées, telles que le psoriasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. M Kristensen CQ Chu DJ Eedy et al. (1993) ArticleTitleLocalization of tumor necrosis factor-alpha (TNF-α) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol 94 354–362 Occurrence Handle1:CAS:528:DyaK2cXivFSquw%3D%3D Occurrence Handle8222328

    CAS  PubMed  Google Scholar 

  2. B Scallon A Cai N Solowski et al. (2002) ArticleTitleBinding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301 418–426 Occurrence Handle10.1124/jpet.301.2.418 Occurrence Handle1:CAS:528:DC%2BD38XjtlKjurw%3D Occurrence Handle11961039

    Article  CAS  PubMed  Google Scholar 

  3. J Keane S Gershon RP Wise et al. (2001) ArticleTitleTuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 1098–1104 Occurrence Handle10.1056/NEJMoa011110 Occurrence Handle1:CAS:528:DC%2BD3MXnsFShsr0%3D Occurrence Handle11596589

    Article  CAS  PubMed  Google Scholar 

  4. JR LaDuca AA Gaspari (2001) ArticleTitleTargeting tumor necrosis factor alpha. New drugs used to modulate inflammatory disease. Dermatol Clin 19 617–635 Occurrence Handle1:CAS:528:DC%2BD3MXotl2msLg%3D Occurrence Handle11705350

    CAS  PubMed  Google Scholar 

  5. PB Sugermann NW Savage GJ Seymour et al. (1996) ArticleTitleIs there a role for tumor necrosis factor-alpha (TNF-alpha) in oral lichen planus? J Oral Pathol Med 25 219–224 Occurrence Handle1:CAS:528:DyaK28XltVSktrc%3D Occurrence Handle8835818

    CAS  PubMed  Google Scholar 

  6. PE Wakefield WD James CP Samlaska et al. (1991) ArticleTitleTumor necrosis factor. J Am Acad Dermatol 24 675–685 Occurrence Handle1:STN:280:By6A3s3hvF0%3D Occurrence Handle1869638

    CAS  PubMed  Google Scholar 

  7. I Tillie–Leblond P Gosset A Janin et al. (1994) ArticleTitleTumor necrosis factor-α release during systemic reaction in cold urticaria. J Allergy Clin Immunol 93 501–509 Occurrence Handle1:STN:280:ByuC28rjsVI%3D Occurrence Handle7509821

    CAS  PubMed  Google Scholar 

  8. C Voigtlander M Luftl G Schuler et al. (2001) ArticleTitleInfliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon–Wilkinson disease). Arch Dermatol 137 1571–1574 Occurrence Handle1:STN:280:DC%2BD38%2FivV2htA%3D%3D Occurrence Handle11735706

    CAS  PubMed  Google Scholar 

  9. MR Smith WE Munger H-F Kung et al. (1990) ArticleTitleDirect evidence for an intracellular role for tumor necrosis factor-α. J Immunol 144 162–169 Occurrence Handle1:STN:280:By%2BC3M7gtVU%3D Occurrence Handle2153163

    CAS  PubMed  Google Scholar 

  10. BA Beutler (1990) ArticleTitleThe tumor necrosis factors: cachectin and lymphotoxin. Hosp Pract (off ED) Feb 15 45–56

    Google Scholar 

  11. BA Beutler IW Milsark A Cerami (1985) ArticleTitleCachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 135 3972–3977 Occurrence Handle1:CAS:528:DyaL28Xjt1yntQ%3D%3D Occurrence Handle2999236

    CAS  PubMed  Google Scholar 

  12. N Tanaka A Fujioka S Tajima et al. (2000) ArticleTitleElafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1 beta and tumour necrosis factor-alpha stimulate its secretion in vitro. Br J Dermatol 143 728–732 Occurrence Handle10.1046/j.1365-2133.2000.03766.x Occurrence Handle1:CAS:528:DC%2BD3cXotlyqsL4%3D Occurrence Handle11069448

    Article  CAS  PubMed  Google Scholar 

  13. RW Groves MH Allen EL Ross et al. (1995) ArticleTitleTumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br J Dermatol 132 345–352 Occurrence Handle1:CAS:528:DyaK2MXkvFyksro%3D Occurrence Handle7536438

    CAS  PubMed  Google Scholar 

  14. Remicade (infliximab) product insert. Centocor, Inc., Malvern, PA, 2002.

  15. S Moretti A Spallanzani L Amato et al. (2002) ArticleTitleVitiligo and epidermal microenvironment: possible involvement of keratinocyte-derived cytokines. Arch Dermatol 138 273–274 Occurrence Handle10.1001/archderm.138.2.273 Occurrence Handle11843662

    Article  PubMed  Google Scholar 

  16. PF Piguet GE Grau P Vassalli (1990) ArticleTitleSubcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am J Pathol 136 103–110 Occurrence Handle1:CAS:528:DyaK3cXhtlOitL8%3D Occurrence Handle1688687

    CAS  PubMed  Google Scholar 

  17. WP Arend (2002) ArticleTitleMode of action of cytokine inhibitors. J Rheumatol 29 16–21

    Google Scholar 

  18. BJ Scallon MA Moore H Trinh et al. (1995) ArticleTitleChimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7 251–259 Occurrence Handle10.1006/cyto.1995.0029 Occurrence Handle1:CAS:528:DyaK2MXls1ait70%3D Occurrence Handle7640345

    Article  CAS  PubMed  Google Scholar 

  19. G Kobbe P Schneider U Rohr et al. (2001) ArticleTitleTreatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 28 47–49 Occurrence Handle10.1038/sj.bmt.1703094 Occurrence Handle1:STN:280:DC%2BD3MvltFajtA%3D%3D Occurrence Handle11498743

    Article  CAS  PubMed  Google Scholar 

  20. C Estrach S Mpofu RJ Moots (2002) ArticleTitleBehçet’s syndrome: response to infliximab after failure to etanercept. Rheumatology 41 1213–1214 Occurrence Handle10.1093/rheumatology/41.10.1213-b Occurrence Handle1:STN:280:DC%2BD38nhtVSmug%3D%3D

    Article  CAS  Google Scholar 

  21. AB Gottlieb S Masud R Ramamurthi et al. (2003) ArticleTitlePharmacodynamic and pharmacokinetic response anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 48 68–75 Occurrence Handle10.1067/mjd.2003.10 Occurrence Handle12522373

    Article  PubMed  Google Scholar 

  22. JDL Williams CEM Griffiths (2002) ArticleTitleCytokine blocking agents in dermatology. Clin Exp Dermatol 27 585–590 Occurrence Handle10.1046/j.1365-2230.2002.01149.x Occurrence Handle1:STN:280:DC%2BD38jgt1yisA%3D%3D Occurrence Handle12464154

    Article  CAS  PubMed  Google Scholar 

  23. Z Tutuncu GJ Morgan A Kavanaugh (2002) ArticleTitleAnti-TNF therapy for other inflammatory conditions. Clin Exp Dermatol 20 S146–S151 Occurrence Handle1:STN:280:DC%2BD38jgtFyjtA%3D%3D

    CAS  Google Scholar 

  24. RJ Farrell SA Shah PJ Lodhavia et al. (2000) ArticleTitleClinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol 95 3490–3497 Occurrence Handle1:CAS:528:DC%2BD3MXmtVWmug%3D%3D Occurrence Handle11151882

    CAS  PubMed  Google Scholar 

  25. PP Sfikakis PG Theodossiadis CG Katsiari et al. (2002) ArticleTitleEffect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358 295–296 Occurrence Handle10.1016/S0140-6736(01)05497-6

    Article  Google Scholar 

  26. LP Robertson P Hickling (2002) ArticleTitleTreatment of recalcitrant orogenital ulceration of Behçet’s syndrome with infliximab. Rheumatology 40 473–474 Occurrence Handle10.1093/rheumatology/40.4.473

    Article  Google Scholar 

  27. A Gül (2001) ArticleTitleBehçet’s disease: an update on the pathogenesis. Clin Exp Dermatol 19 S6–S12

    Google Scholar 

  28. N Sayinalp OI Özcebe O Özdemir et al. (1996) ArticleTitleCytokines in Behçet’s disease. J Rheumatol 23 321–323 Occurrence Handle1:STN:280:ByiD3snjvFU%3D Occurrence Handle8882039

    CAS  PubMed  Google Scholar 

  29. PP Sfikakis (2002) ArticleTitleBehçet’s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61 ii51–ii53 Occurrence Handle12379622

    PubMed  Google Scholar 

  30. PH Goossens RJ Verburg FC Breedveld (2002) ArticleTitleRemission of Behçet’s syndrome with tumour necrosis factor α blocking therapy. Ann Rheum Dis 60 637 Occurrence Handle10.1136/ard.60.6.637

    Article  Google Scholar 

  31. M Rozenbaum I Rosner E Portnoy (2002) ArticleTitleRemission of Behçet’s syndrome with TNF[alpha] blocking treatment. Ann Rheum Dis 61 283–284 Occurrence Handle10.1136/ard.61.3.283-a Occurrence Handle1:STN:280:DC%2BD387ivFyisA%3D%3D

    Article  CAS  Google Scholar 

  32. M Alecu L Geleriu G Coman et al. (1998) ArticleTitleThe interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor alpha serological levels in localized and systemic sclerosis. Rom J Intern Med 36 251–259 Occurrence Handle1:STN:280:DC%2BD3c3otF2gsg%3D%3D Occurrence Handle10822522

    CAS  PubMed  Google Scholar 

  33. AP Hughes JM Jackson JP Callen (2000) ArticleTitleClinical features and treatment of peristomal pyoderma gangrenosum. JAMA 284 1546–1548 Occurrence Handle10.1001/jama.284.12.1546 Occurrence Handle1:STN:280:DC%2BD3cvotlKqug%3D%3D Occurrence Handle11000649

    Article  CAS  PubMed  Google Scholar 

  34. P Hervé M Flesch P Tiberghien et al. (1992) ArticleTitlePhase I–II trial of a monoclonal anti-tumor necrosis factor α antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 79 3362–3368 Occurrence Handle1596576

    PubMed  Google Scholar 

  35. Boh E, Sherrod J, Safah H, et al. Successful use of infliximab in a patient with graft versus host disease [poster]. World Congress of Dermatology, Paris, France, July 1-5, 2002.

  36. IK Altunay G Gokdemir A Kurt et al. (2002) ArticleTitleHidradenitis suppurativa and squamous cell carcinoma. Dermatol Surg 28 88–90 Occurrence Handle10.1046/j.1524-4725.2002.01090.x Occurrence Handle11991278

    Article  PubMed  Google Scholar 

  37. MS Daoud CH Dicken (1999) Apocrine Glands. IM Freedberg AZ Eisen K Wolff (Eds) Fitzpatrick’s Dermatology in General Medicine. EditionNumber5 McGraw-Hill New York

    Google Scholar 

  38. I Jansen P Altmeyer G Piewig (2001) ArticleTitleAcne inversa (alias hidradenitis suppurativa). J Eur Acad Dermatol Venereol 15 532–540 Occurrence Handle10.1046/j.1468-3083.2001.00303.x Occurrence Handle1:STN:280:DC%2BD387ht1Siuw%3D%3D Occurrence Handle11843212

    Article  CAS  PubMed  Google Scholar 

  39. JM Von derWerth GBE Jemec (2001) ArticleTitleMorbidity in patients with hidradenitis suppurativa. Br J Dermatol 144 809–813 Occurrence Handle10.1046/j.1365-2133.2001.04137.x Occurrence Handle1:STN:280:DC%2BD3M3gvF2lsA%3D%3D Occurrence Handle11298541

    Article  CAS  PubMed  Google Scholar 

  40. F Martínez P Nos S Benlloch et al. (2001) ArticleTitleHidradenitis suppurativa and Crohn’s disease: response to treatment with infliximab. Inflamm Bowel Dis 7 323–326 Occurrence Handle10.1097/00054725-200111000-00008 Occurrence Handle11720323

    Article  PubMed  Google Scholar 

  41. KH Katsanos DK Christodoulou EV Tsianos (2002) ArticleTitleAxillary hidradenitis suppurativa successfully treated with infliximab in a Crohn’s disease patient. Am J Gastroenterol 97 2155–2156 Occurrence Handle12190206

    PubMed  Google Scholar 

  42. Sullivan TP, Welsh E, Kerdel FA, et al. Infliximab for hidradenitis suppurativa [poster]. World Congress of Dermatology, Paris, France July 1–5, 2002.

  43. Humeniuk JM, Gliptis EG. Infliximab in the treatment of panniculitis. World Congress of Dermatology, Paris, France, July 1–5, 2002.

  44. HS Yu KL Chang CL Yu et al. (1997) ArticleTitleAlterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol 108 527–529 Occurrence Handle10.1111/1523-1747.ep12289743 Occurrence Handle1:CAS:528:DyaK2sXisVags7s%3D Occurrence Handle9077486

    Article  CAS  PubMed  Google Scholar 

  45. W Löntz A Sirsjö M Liu et al. (1995) ArticleTitleIncreased mRNA expression of maganese superoxide dismutase in psoriasis skin lesions and in cultured human keratinocytes exposed to IL-1β and TNF-α. Free Radic Biol Med 18 349–355 Occurrence Handle10.1016/0891-5849(94)E0124-2 Occurrence Handle7744320

    Article  PubMed  Google Scholar 

  46. BJ Nickoloff GD Karabin JNWN Barker et al. (1991) ArticleTitleCellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 138 129–140 Occurrence Handle1:CAS:528:DyaK3MXhsVWhsbk%3D Occurrence Handle1702929

    CAS  PubMed  Google Scholar 

  47. P Ettehadi MW Greaves D Wallach et al. (1994) ArticleTitleElevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions. Clin Exp Immunol 96 146–151 Occurrence Handle1:CAS:528:DyaK2cXktVOit7w%3D Occurrence Handle8149659

    CAS  PubMed  Google Scholar 

  48. B Kirby AM Marsland AJ Carmichael et al. (2001) ArticleTitleSuccessful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 26 27–29 Occurrence Handle10.1046/j.1365-2230.2001.00753.x Occurrence Handle1:STN:280:DC%2BD3M7mtVamtw%3D%3D Occurrence Handle11260172

    Article  CAS  PubMed  Google Scholar 

  49. FC Powell M O’Kane (2002) ArticleTitleManagement of pyoderma gangrenosum. Dermatol Clin 20 347–355 Occurrence Handle12120448

    PubMed  Google Scholar 

  50. R Nussbaum JG Krueger (2002) Treatment of inflammatory dermatoses with novel biologic agents: a primer. WD James CJ Cockerell ME Maloney (Eds) Advances in Dermatology. EditionNumber18 Mosby St. Louis: CV.

    Google Scholar 

  51. JM Weinberg R Saini (2003) ArticleTitleBiologic therapy for psoriasis: the tumor necrosis factor inhibitors-infliximab and etanercept. Cutis 71 25–29 Occurrence Handle12553627

    PubMed  Google Scholar 

  52. PJ Mease (2002) ArticleTitleTumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 61 298–304 Occurrence Handle10.1136/ard.61.4.298 Occurrence Handle1:CAS:528:DC%2BD38XjtVertLk%3D Occurrence Handle11874829

    Article  CAS  PubMed  Google Scholar 

  53. CG Jackson (2001) ArticleTitleImmunomodulating drugs in the management of psoriatic arthritis. Am J Clin Dermatol 2 367–375 Occurrence Handle1:STN:280:DC%2BD38%2FktlaktA%3D%3D Occurrence Handle11770391

    CAS  PubMed  Google Scholar 

  54. L Zabraniecki B Fournié (2001) ArticleTitleTNFα inhibition in psoriatic arthritis: cause for hope. Joint Bone Spine 68 106–108 Occurrence Handle10.1016/S1297-319X(01)00257-3 Occurrence Handle1:STN:280:DC%2BD3MvpsVGitg%3D%3D Occurrence Handle11324924

    Article  CAS  PubMed  Google Scholar 

  55. Gottlieb, AB, Romano, P, Chaudhari, U, et al. Infliximab prevents relapse of moderate to severe psoriasis in responding patients [poster]. World Congress of Dermatology, Paris, France, July 1–5, 2002.

  56. CJ Oh KM Das AB Gottlieb (2000) ArticleTitleTreatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 42 829–830 Occurrence Handle10.1067/mjd.2000.105948 Occurrence Handle1:STN:280:DC%2BD3c3jvF2qtA%3D%3D Occurrence Handle10775863

    Article  CAS  PubMed  Google Scholar 

  57. RE Schopf H Aust J Knop (2002) ArticleTitleTreatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α, infliximab. J Am Acad Dermatol 46 886–891 Occurrence Handle10.1067/mjd.2002.120472 Occurrence Handle12063486

    Article  PubMed  Google Scholar 

  58. U Chaudhari P Romano LD Mulcahy et al. (2001) ArticleTitleEfficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 357 1842–1847 Occurrence Handle10.1016/S0140-6736(00)04954-0 Occurrence Handle1:CAS:528:DC%2BD3MXkt1Khs74%3D Occurrence Handle11410193

    Article  CAS  PubMed  Google Scholar 

  59. E Cauza M Spak K Cauza et al. (2002) ArticleTitleTreatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int 22 227–232 Occurrence Handle10.1007/s00296-002-0246-3 Occurrence Handle1:CAS:528:DC%2BD38XosFWlsbg%3D Occurrence Handle12426660

    Article  CAS  PubMed  Google Scholar 

  60. R Mang H Stege T Ruzicka et al. (2002) ArticleTitleResponse of severe psoriasis to infliximab. Dermatology 204 156–157 Occurrence Handle10.1159/000051840 Occurrence Handle1:CAS:528:DC%2BD38XjtFSjsbc%3D Occurrence Handle11937748

    Article  CAS  PubMed  Google Scholar 

  61. ALJ Ogilvie C Antoni C Dechant et al. (2001) ArticleTitleTreatment of psoriatic arthritis with antitumor necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 144 587–589 Occurrence Handle10.1046/j.1365-2133.2001.04089.x Occurrence Handle1:CAS:528:DC%2BD3MXivVOntrk%3D Occurrence Handle11260020

    Article  CAS  PubMed  Google Scholar 

  62. MR Newland A Weinstein F Kerdel (2002) ArticleTitleRapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 41 449–452 Occurrence Handle10.1046/j.1365-4362.2002.01543.x Occurrence Handle1:CAS:528:DC%2BD38Xms1Gjsb0%3D Occurrence Handle12121565

    Article  CAS  PubMed  Google Scholar 

  63. MH Tan M Gordon O Lebwohl et al. (2001) ArticleTitleImprovement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 137 930–933 Occurrence Handle1:STN:280:DC%2BD3MvitlyrsA%3D%3D Occurrence Handle11453813

    CAS  PubMed  Google Scholar 

  64. F Grange F Gjilali–Bouzina AM Weiss et al. (2002) ArticleTitleCorticosteroid-resistant pyoderma gangrenosum associated with Crohn’s disease: rapid cure with infliximab. Dermatology 205 278–280 Occurrence Handle10.1159/000065860 Occurrence Handle1:CAS:528:DC%2BD38Xot1Smsbg%3D Occurrence Handle12399677

    Article  CAS  PubMed  Google Scholar 

  65. K Wolff G Stingl (1999) Pyoderma gangrenosum. IM Freedberg AZ Eisen K Wolff (Eds) Fitzpatrick’s Dermatology in General Medicine. EditionNumber5 McGraw-Hill New York

    Google Scholar 

  66. JT Trent RS Kirsner (2001) ArticleTitleDiagnosing pyoderma gangrenosum. Adv Skin Wound Care 14 151–153 Occurrence Handle10.1097/00129334-200105000-00015 Occurrence Handle1:STN:280:DC%2BD387nt1OqtQ%3D%3D Occurrence Handle11905982

    Article  CAS  PubMed  Google Scholar 

  67. JK Triantafillidis P Cheracakis M Sklavaina et al. (2002) ArticleTitleFavorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol 37 863–865 Occurrence Handle1:STN:280:DC%2BD38vjtlGlsw%3D%3D Occurrence Handle12190104

    CAS  PubMed  Google Scholar 

  68. Límová M, Bolce R. Management of pyoderma gangrenosum with infliximab (Remicade) [poster]. World Congress of Dermatology Paris, France, July 1–5, 2002.

  69. DG Sheldon LL Sawchuk RA Kozarek et al. (2000) ArticleTitleTwenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg 135 564–568 Occurrence Handle10.1001/archsurg.135.5.564 Occurrence Handle1:STN:280:DC%2BD3c3msFGlsw%3D%3D Occurrence Handle10807281

    Article  CAS  PubMed  Google Scholar 

  70. LA Batres P Mamula RN Baldassano (2002) ArticleTitleResolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr 34 558–560 Occurrence Handle10.1097/00005176-200205000-00016 Occurrence Handle12050585

    Article  PubMed  Google Scholar 

  71. AD Wagner J Andresen MC Jendro et al. (2002) ArticleTitleSustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 46 1965–1968 Occurrence Handle10.1002/art.10539 Occurrence Handle12124882

    Article  PubMed  Google Scholar 

  72. Z Karolyi I Harhai N Eros (2001) ArticleTitle[Dermatologic aspects of SAPHO-syndrome]. Orv Hetil 142 1801–1804 Occurrence Handle1:STN:280:DC%2BD3MrislGmsQ%3D%3D Occurrence Handle11573450

    CAS  PubMed  Google Scholar 

  73. I Olivieri A Padula G Ciancio et al. (2002) ArticleTitleSuccessful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis 61 375–376 Occurrence Handle10.1136/ard.61.4.375 Occurrence Handle1:STN:280:DC%2BD387jvVOksw%3D%3D Occurrence Handle11874849

    Article  CAS  PubMed  Google Scholar 

  74. OP Sharma (1999) Sarcoidosis of the skin. IM Freedberg AZ Eisen K Wolff (Eds) Fitzpatrick’s Dermatology in General Medicine. EditionNumber5 McGraw-Hill New York

    Google Scholar 

  75. MC Cook (2002) ArticleTitleInfliximab therapy for complicated sarcoidosis. Ann Intern Med 137 296 Occurrence Handle10.1063/1.478378

    Article  Google Scholar 

  76. JA Petterson DW Zochodne RB Bell et al. (2002) ArticleTitleRefractory neurosarcoidosis responding to infliximab. Neurology 59 1660–1661 Occurrence Handle12451224

    PubMed  Google Scholar 

  77. RP Baughman EE Lower (2001) ArticleTitleInfliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 18 70–74 Occurrence Handle1:STN:280:DC%2BD3M3lsFGlsg%3D%3D Occurrence Handle11354550

    CAS  PubMed  Google Scholar 

  78. AMF Yee MB Pochapin (2001) ArticleTitleTreatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-α therapy. Ann Intern Med 135 27–31 Occurrence Handle1:STN:280:DC%2BD3MvgsVWjug%3D%3D Occurrence Handle11434729

    CAS  PubMed  Google Scholar 

  79. E Delaporte JF Colombel C Nguyen–Mailfer et al. (1992) ArticleTitleSubcorneal pustular dermatosis in a patient with Crohn’s disease. Acta Derm Venereol 72 301–302 Occurrence Handle1:STN:280:ByyD3szpvVY%3D Occurrence Handle1357895

    CAS  PubMed  Google Scholar 

  80. JJ Grob JL Mege C Capo et al. (1991) ArticleTitleRole of tumor necrosis factor-alpha in Sneddon–Wilkinson subcorneal pustular dermatosis. A model of neutrophil priming in vivo. J Am Acad Dermatol 25 944–947 Occurrence Handle1:STN:280:By2C3crltFw%3D Occurrence Handle1761776

    CAS  PubMed  Google Scholar 

  81. O Correia L Delgado IL Barbosa et al. (2002) ArticleTitleIncreased interleukin 10, tumor necrosis factor α, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol 47 58–62 Occurrence Handle10.1067/mjd.2002.120473 Occurrence Handle12077582

    Article  PubMed  Google Scholar 

  82. P Paquet F Paquet W Al Saleh et al. (2000) ArticleTitleImmunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol 22 413–417 Occurrence Handle1:STN:280:DC%2BD3crgtFGntg%3D%3D Occurrence Handle11048976

    CAS  PubMed  Google Scholar 

  83. PO Fritsch R Ruiz–Maldonado (1999) Stevens–Johnson syndrome—toxic epidermal necrolysis. IM Freedberg AZ Eisen K Wolff (Eds) Fitzpatrick’s Dermatology in General Medicine. EditionNumber5 McGraw-Hill New York

    Google Scholar 

  84. N Craven (2002) Toxic epidermal necrolysis and Stevens–Johnson syndrome. M Lebwohl WR Heyman J Berth–Jones (Eds) Treatment of Skin Disease. Comprehensive therapeutic strategies. Harcourt Publishers Limited London

    Google Scholar 

  85. P Redondo I De Felipe A De la Pena et al. (1997) ArticleTitleDrug-induced hypersensitivity syndrome and toxic epidermal necrolysis: treatment with N-acetylcysteine Br J Dermatol 136 645–646 Occurrence Handle1:STN:280:ByiA3c%2Fps1w%3D Occurrence Handle9155988

    CAS  PubMed  Google Scholar 

  86. P Ghislain J Roujeau (2002) ArticleTitleTreatment of severe drug reactions: Stevens–Johnson Syndrome, Toxic Epidermal Necrolysis and Hypersensitivity Syndrome. Dermatol Online J 8 5

    Google Scholar 

  87. M Fischer E Fiedler WC Marsch et al. (2002) ArticleTitleAntitumour necrosis factor-α antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 146 707–708 Occurrence Handle10.1046/j.1365-2133.2002.46833.x Occurrence Handle1:STN:280:DC%2BD383ot1CgtA%3D%3D Occurrence Handle11966713

    Article  CAS  PubMed  Google Scholar 

  88. P Bartolucci J Ramanoelina P Cohen et al. (2002) ArticleTitleEfficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 41 1126–1132 Occurrence Handle10.1093/rheumatology/41.10.1126 Occurrence Handle1:CAS:528:DC%2BD38XovFOqur8%3D Occurrence Handle12364631

    Article  CAS  PubMed  Google Scholar 

  89. BF Mandell GS Hoffman (1999) Systemic necrotizing arteritis. IM Freedberg AZ Eisen K Wolff (Eds) Fitzpatrick’s Dermatology in General Medicine. EditionNumber5 McGraw–Hill New York

    Google Scholar 

  90. P Lamprecht J Voswinkel T Lilienthal et al. (2002) ArticleTitleEffectiveness of TNF-α blockade with infliximab in refractory Wegener’s granulomatosis. Rheumatology 41 1303–1307 Occurrence Handle10.1093/rheumatology/41.11.1303 Occurrence Handle1:CAS:528:DC%2BD38XosFOgsr8%3D Occurrence Handle12422004

    Article  CAS  PubMed  Google Scholar 

  91. P Lamprecht O Arbach J Voswinkel et al. (2002) ArticleTitleInduction of remission with infliximab in therapy-refractory Wegener’s granulomatosis—Follow-up of six patients. Dtsch Med Wochenschr 127 1876–1880 Occurrence Handle10.1055/s-2002-34065 Occurrence Handle1:STN:280:DC%2BD38vnt1Cnsw%3D%3D Occurrence Handle12235553

    Article  CAS  PubMed  Google Scholar 

  92. MCY Heng M Khoo A Cooperman et al. (1994) ArticleTitleHaemorrhagic cellulitis: a syndrome associated with tumor necrosis factor-α. Br J Dermatol 130 65–74 Occurrence Handle1:STN:280:ByuC3sjlvFE%3D Occurrence Handle8305320

    CAS  PubMed  Google Scholar 

  93. A Zalewska E Brzezinska–Blaszczyk A Omulecki et al. (1997) ArticleTitleFunctional studies of skin mast cells in lichen planus. Arch Dermatol Res 289 261–264 Occurrence Handle10.1007/s004030050190 Occurrence Handle1:CAS:528:DyaK2sXjtFSgurw%3D Occurrence Handle9164635

    Article  CAS  PubMed  Google Scholar 

  94. C Simark–Mattsson G Bergenholtz M Jontell et al. (1999) ArticleTitleDistribution of interleukin-2, –4, –10, tumour necrosis factor-alpha and transforming growth factor-beta mRNAs in oral lichen planus. Arch Oral Biol 44 499–507 Occurrence Handle10.1016/S0003-9969(99)00013-8 Occurrence Handle1:CAS:528:DyaK1MXktFGmsb0%3D Occurrence Handle10401528

    Article  CAS  PubMed  Google Scholar 

  95. M Simon SuffixJr MS Gruschwitz (1997) ArticleTitle In situ expression and serum levels of tumour necrosis factor alpha receptors in patients with lichen planus. Acta Derm Venereol 77 191–193 Occurrence Handle9188868

    PubMed  Google Scholar 

  96. A Sklavounou E Chrysomali A Scorilas et al. (2000) ArticleTitleTNF-alpha expression and apoptosis-regulating proteins in oral lichen planus: a comparative immunohistochemical evaluation. J Oral Pathol Med 29 370–375 Occurrence Handle10.1034/j.1600-0714.2000.290802.x Occurrence Handle1:CAS:528:DC%2BD3cXmsFSrtro%3D Occurrence Handle10972345

    Article  CAS  PubMed  Google Scholar 

  97. C Feliciani P Toto P Amerio et al. (1999) ArticleTitle In vitro C3 mRNA expression in pemphigus vulgaris: complement activation is increased by IL-1α and TNF-α. J Cut Med Surg 3 140–144 Occurrence Handle1:STN:280:DyaK1M7ot1GmtQ%3D%3D

    CAS  Google Scholar 

  98. E Lòpez–Robles E Avalos–Díaz E Vega–Memije et al. (2001) ArticleTitleTNFα and IL-6 are mediators in the blistering process of pemphigus. Int J Dermatol 40 185–188 Occurrence Handle10.1046/j.1365-4362.2001.01083.x Occurrence Handle11422521

    Article  PubMed  Google Scholar 

  99. C Feliciani P Toto P Amerio et al. (2000) ArticleTitle In vitro and in vivo expression of interleukin-1α and tumor necrosis factor-α in pemphigus vulgaris: interleukin-1α and tumor necrosis factor-α are involved in acantholysis. J Invest Dermatol 114 71–77 Occurrence Handle10.1046/j.1523-1747.2000.00835.x Occurrence Handle1:CAS:528:DC%2BD3cXisFKlt7s%3D Occurrence Handle10620118

    Article  CAS  PubMed  Google Scholar 

  100. F Ameglio L D’Auria P Cordiali–Fei et al. (1997) ArticleTitleBullous pemphigoid and pemphigus vulgaris: correlated behavior of serum VEGF, E-selectin and TNF-alpha levels. J Biol Regul Homeost Agents 11 148–153 Occurrence Handle1:STN:280:DyaK1c3ktlChsw%3D%3D Occurrence Handle9582615

    CAS  PubMed  Google Scholar 

  101. LE Rhodes IA Hashim PJ McLaughlin et al. (1999) ArticleTitleBlister fluid cytokines in cutaneous inflammatory bullous disorders. Acta Derm Venereol 79 288–290 Occurrence Handle10.1080/000155599750010689 Occurrence Handle1:STN:280:DyaK1MzlslSmtw%3D%3D Occurrence Handle10429986

    Article  CAS  PubMed  Google Scholar 

  102. JR Stanley (1999) Pemphigus. IM Freedberg AZ Eisen K Wolff (Eds) Fitzpatrick’s Dermatology in General Medicine. EditionNumber5 McGraw–Hill New York

    Google Scholar 

  103. JR Stanley (1999) Bullous pemphigoid. IM Freedberg AZ Eisen K Wolff (Eds) Fitzpatrick’s Dermatology in General Medicine. EditionNumber5 McGraw–Hill New York

    Google Scholar 

  104. H Umehara S Kumagai M Murakami et al. (1990) ArticleTitleEnhanced production of interleukin-1 and tumor necrosis factor alpha by cultured peripheral blood monocytes from patients with scleroderma. Arthritis Rheum 33 893–897 Occurrence Handle1:STN:280:By%2BA3czjs1A%3D Occurrence Handle2363741

    CAS  PubMed  Google Scholar 

  105. BW Needleman FM Wigley RW Stair (1992) ArticleTitleInterleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 35 67–72 Occurrence Handle1:STN:280:By2C3MfhsVU%3D Occurrence Handle1731816

    CAS  PubMed  Google Scholar 

  106. S Della Bella M Molteni B Mascagni et al. (1997) ArticleTitleCytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine. Clin Exp Rheum 15 135–141 Occurrence Handle1:STN:280:ByiA2c%2Fjs1E%3D

    CAS  Google Scholar 

  107. B Hermes AK Prochazke N Haas et al. (1999) ArticleTitleUpregulation of TNF-α and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol 103 307–314 Occurrence Handle1:STN:280:DyaK1M7jsF2quw%3D%3D Occurrence Handle9949323

    CAS  PubMed  Google Scholar 

  108. A Frezzolini O De Pità N Cassano et al. (2002) ArticleTitleEvaluation of inflammatory parameters in physical urticarias and effects of an anti-inflammatory/antiallergic treatment. Int J Dermatol 41 431–438 Occurrence Handle10.1046/j.1365-4362.2002.01441.x Occurrence Handle12121561

    Article  PubMed  Google Scholar 

  109. RJ Barlow EL Ross D Macdonald et al. (1994) ArticleTitleAdhesion molecule expression and the inflammatory cell infiltrate in delayed pressure urticaria. Br J Dermatol 131 341–347 Occurrence Handle1:CAS:528:DyaK2cXmslyltb4%3D Occurrence Handle7522516

    CAS  PubMed  Google Scholar 

  110. RB Bressler (1995) ArticleTitlePathophysiology of chronic urticaria. Immunol Allergy Clin North Am 15 659–677

    Google Scholar 

  111. Y Kano M Orihara T Shiohara (1998) ArticleTitleCellular and molecular dynamics in exercise-induced urticarial vasculitis lesions. Arch Dermatol 134 62–67 Occurrence Handle10.1001/archderm.134.1.62 Occurrence Handle1:STN:280:DyaK1c7htFGltg%3D%3D Occurrence Handle9449911

    Article  CAS  PubMed  Google Scholar 

  112. SB Hanauer (1999) ArticleTitleReview article: safety of Infliximab in clincal trials. Aliment Pharmacol Ther 13 16–22 Occurrence Handle10.1046/j.1365-2036.1999.00027.x Occurrence Handle1:CAS:528:DyaK1MXmsl2iu7k%3D Occurrence Handle10597335

    Article  CAS  PubMed  Google Scholar 

  113. RD Cohen JF Tsang SB Hanauer (2000) ArticleTitleInfliximab in Crohn’s disease: first anniversary clinical experience. Am J Gastroenterol 95 3469–3477 Occurrence Handle1:CAS:528:DC%2BD3MXmtVWmtA%3D%3D Occurrence Handle11151879

    CAS  PubMed  Google Scholar 

  114. Centocor. Adverse events in patients treated with Remicade, 2002 (data on file).

  115. I Soykan C Ertan A Ozden (2000) ArticleTitleSevere anaphylactic reaction to infliximab: report of a case. Am J Gastroenterol 95 2395–2396 Occurrence Handle10.1016/S0002-9270(00)01141-2 Occurrence Handle1:STN:280:DC%2BD3cvltFGksg%3D%3D

    Article  CAS  Google Scholar 

  116. PJ Charles RJT Smeenk J De Jong et al. (2002) ArticleTitleAssessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α. Arthritis Rheum. 43 2383–2390 Occurrence Handle10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.3.CO;2-4

    Article  Google Scholar 

  117. Y Ali S Shah (2002) ArticleTitleInfliximab-induced systemic lupus erythematous. Ann Intern Med 137 625–626

    Google Scholar 

  118. R Maini EW St Clair F Breedveld et al. (1999) ArticleTitleInfliximab (Chimeric anti-tumor necrosis factor [alpha] monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 354 1932–1939 Occurrence Handle10.1016/S0140-6736(99)05246-0 Occurrence Handle1:CAS:528:DC%2BD3cXit1Oquw%3D%3D Occurrence Handle10622295

    Article  CAS  PubMed  Google Scholar 

  119. EN Liberopoulos AA Drosos MS Elisaf (2002) ArticleTitleExacerbation of tuberculosis enteritis after treatment with infliximab. Am J Med 113 615 Occurrence Handle10.1016/S0002-9343(02)01205-6 Occurrence Handle12459414

    Article  PubMed  Google Scholar 

  120. EZ Lobel BI Korelitz JI Warman (2003) ArticleTitleRed man syndrome and infliximab. J Clin Gastroenterol 36 186 Occurrence Handle10.1097/00004836-200302000-00024

    Article  Google Scholar 

  121. H Marotte JE Charrin P Miossec (2001) ArticleTitleInfliximab-induced aseptic meningitis. Lancet 358 1784 Occurrence Handle10.1016/S0140-6736(01)06810-6 Occurrence Handle1:STN:280:DC%2BD3MnoslOrsA%3D%3D Occurrence Handle11734240

    Article  CAS  PubMed  Google Scholar 

  122. AS Kashyap S Kashyap (2002) ArticleTitleInfliximab-induced aseptic meningitis. Lancet 359 1252 Occurrence Handle10.1016/S0140-6736(02)08241-7 Occurrence Handle1:STN:280:DC%2BD383hvVenuw%3D%3D

    Article  CAS  Google Scholar 

  123. WV Crandall LM Mackner (2003) ArticleTitleInfusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 17 75–84 Occurrence Handle10.1046/j.1365-2036.2003.01411.x Occurrence Handle1:CAS:528:DC%2BD3sXhtlKrsb0%3D

    Article  CAS  Google Scholar 

  124. MC Stephens MA Shepanski P Mamula et al. (2003) ArticleTitleSafety and steroid-sparing experience using infliximab for Crohn’s disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 98 104–111 Occurrence Handle1:CAS:528:DC%2BD3sXhsVWrsrw%3D Occurrence Handle12526944

    CAS  PubMed  Google Scholar 

  125. MP Stevens WW Lee WS Makarowski et al. (2002) ArticleTitleInfliximab in the treatment of psoriatic arthritis and psoriasis. . . .

    Google Scholar 

  126. RP O’Quinn JL Miller (2002) ArticleTitleThe effectiveness of tumor necrosis factor α antibody (infliximab) in treating recalcitrant psoriasis. Arch Dermatol 138 644–648 Occurrence Handle10.1001/archderm.138.5.644 Occurrence Handle12020227

    Article  PubMed  Google Scholar 

  127. BE Elewski (2002) ArticleTitleInfliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol 47 796–797 Occurrence Handle10.1067/mjd.2002.128382 Occurrence Handle12399781

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Dermatology, Department of Medicine, Sunnybrook and Women’s College Health Sciences Center (Sunnybrook site) and the University of Toronto, Toronto, Canada

    Aditya K. Gupta

  2. Mediprobe Laboratories Inc., London, Ontario, Canada

    Aditya K. Gupta & Alayne R. Skinner

Authors
  1. Aditya K. Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alayne R. Skinner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aditya K. Gupta.

Additional information

Funding for the publication of this article was provided by Centocor, Inc., Malvern, PA, USA.

About this article

Cite this article

Gupta, A.K., Skinner, A.R. A Review of the Use of Infliximab to Manage Cutaneous Dermatoses. JCMS 8, 77–89 (2004). https://doi.org/10.1007/s10227-004-0115-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10227-004-0115-7

Keywords

Search

Navigation